These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1695113)

  • 1. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
    Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
    Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leu-19 in myeloma--a new role for an old antibody.
    Wetter O; Brandhorst D; Reiter W
    Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
    Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
    Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cell activity in monoclonal gammopathies: relation to disease activity.
    Osterborg A; Nilsson B; Björkholm M; Holm G; Mellstedt H
    Eur J Haematol; 1990 Sep; 45(3):153-7. PubMed ID: 1699786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
    Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A
    J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma.
    Sonneveld P; Durie BG; Lokhorst HM; Frutiger Y; Schoester M; Vela EE
    Br J Haematol; 1993 Jan; 83(1):63-7. PubMed ID: 7679588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells.
    Barker HF; Hamilton MS; Ball J; Drew M; Franklin IM
    Br J Haematol; 1992 Jul; 81(3):331-5. PubMed ID: 1382543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
    Bergsagel PL; Smith AM; Szczepek A; Mant MJ; Belch AR; Pilarski LM
    Blood; 1995 Jan; 85(2):436-47. PubMed ID: 7529064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.
    Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G
    Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
    Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
    Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of natural-killer-associated and activation antigens in multiple myeloma.
    Gonzalez M; San Miguel JF; Gascon A; Moro MJ; Hernandez JM; Ortega F; Jimenez R; Guerras L; Romero M; Casanova F
    Am J Hematol; 1992 Feb; 39(2):84-9. PubMed ID: 1550111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Kovarova L; Buresova I; Buchler T; Suska R; Pour L; Zahradova L; Penka M; Hajek R
    Neoplasma; 2009; 56(6):526-32. PubMed ID: 19728762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
    Gazitt Y; Reading CC; Hoffman R; Wickrema A; Vesole DH; Jagannath S; Condino J; Lee B; Barlogie B; Tricot G
    Blood; 1995 Jul; 86(1):381-9. PubMed ID: 7540887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of myeloma cells in the peripheral blood using flow cytometry].
    Adam Z; Klabusay M; Vorlícek J; Hájek R
    Vnitr Lek; 1997 Sep; 43(9):592-8. PubMed ID: 9750468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
    Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
    Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.
    Van Riet I; De Waele M; Remels L; Lacor P; Schots R; Van Camp B
    Br J Haematol; 1991 Nov; 79(3):421-7. PubMed ID: 1721526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cells composing plasmacytoma have phenotypes different from those of myeloma cells.
    Sakai A; Fujii T; Noda M; Hyodo H; Oda K; Kimura A
    Am J Hematol; 1996 Dec; 53(4):251-3. PubMed ID: 8948665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.